An ancient RNA-guided system could simplify delivery of gene editing therapies | Broad Institute
broadinstitute.org · 561 words · saved by 1 readers
The programmable proteins are compact, modular, and can be directed to modify DNA in human cells.
Broad Institute's gene-editing technologies—CRISPR-Cas9, base editing, and prime editing—are being tested in more than 25 clinical trials to treat or cure leukemias, rare genetic diseases, high cholesterol, and other conditions. NIH-funded discoveries from the Broad Institute are powering nearly 20 clinical trials from companies testing new treatments for diseases like cancer and heart disease. Broad Institute developed a technology — partly supported by NIH funding — that can detect trace amounts of cancer DNA from blood tests and help cancer patients find out their risk of disease…
related reading
- Gap Mapgap-map.org
- Medical breakthroughs in 2025 - by Saloni Dattaniscientificdiscovery.dev
- The Frontier in 2025renaissancephilanthropy.org
- CRISPR Gene Therapy: Applications, Limitations, and Implications for the Futurencbi.nlm.nih.gov
- Significantly Enhancing Adult Intelligence With Gene Editing May Be Possible — LessWronglesswrong.com
- Nature's drug database - The Works in Progress Newsletterworksinprogress.news
- GC-Mainarep.med.harvard.edu
- News — Pacific 8 Venturespac8.com
- Going Founder Mode On Cancer - by Elliot Hershbergcenturyofbio.com
- Large NIH Grant Supports CRISPR-based Gene Therapy Development for Brain Diseases | Yale School of Medicinemedicine.yale.edu
- New tools for programming biology - by Elliot Hershbergcenturyofbio.com
- Combining AI and Crispr Will Be Transformationalwired.com